Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
The Economy
Bank Stresses Equivalent to an Interest Rate Hike: Powell
The Fed chair said it was too soon to tell how monetary policy should respond to recent banking turmoil.
By
Vincent Ryan
| March 23, 2023
Read More
Resources
Reports
Reports
2023
2022
Featured
The Economy
Bank Stresses Equivalent to an Interest Rate Hike: Powell
The Fed chair said it was too soon to tell how monetary policy should respond to recent banking turmoil.
By
Vincent Ryan
| March 23, 2023
Read More
Sign Up
Menu
Reports
2023
2022
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
Sign Up
Sponsored by
biotech
Q&A
From Analyst to CFO by Age 30: Michelle Gilson
Arcellx’s Gilson is using her experience as a research analyst to succeed as a first-time CFO.
By
Sandra Beckwith
| September 8, 2022
Read More
Supply Chain
uBiome Founders Charged With $60 Million Fraud
The SEC says Jessica Richman and Zachary Apte misrepresented that their biotech startup was generating reliable revenue from insurance reimbursements.
By
Matthew Heller
| March 19, 2021
Read More
M&A
Merck Buys OncoImmune in COVID Treatment Move
The $425 million deal gives Merck access to a promising therapy for treating seriously ill COVID-19 patients.
By
Matthew Heller
| November 23, 2020
Read More
Financial Performance
Moderna Q3 Revenues Beat Estimates
The biotech is preparing for the global launch of its potential COVID-19 vaccine.
By
Lauren Muskett
| October 29, 2020
Read More
M&A
Bayer to Buy Gene Therapy Company AskBio
The pharma giant could pay as much as $4 billion if performance targets are met.
By
Lauren Muskett
| October 26, 2020
Read More
Risk & Compliance
Biotech Exec Charged With COVID Test Fraud
The SEC says Arrayit President Mark Schena falsely claimed the company had developed a test and it was awaiting emergency FDA approval.
By
Matthew Heller
| September 28, 2020
Read More
M&A
Illumina Buys Cancer Test Startup Grail for $8B
The deal will move Illumina “deeper into the application of its gene-sequencing technology to the diagnosis and treatment of patients."
By
Matthew Heller
| September 21, 2020
Read More
Risk & Compliance
Alexion Fined $21M in Foreign Corruption Probe
The SEC says the biotech firm made improper payments to Turkish and Russian officials to secure favorable treatment for its main drug.
By
Matthew Heller
| July 3, 2020
Read More
Risk & Compliance
Moderna Stock Soars on COVID Vaccine Results
Interim data from a Phase 1 study showed Moderna's vaccine candidate stimulated an immune response against the virus in people.
By
Matthew Heller
| May 18, 2020
Read More
Risk & Compliance
SEC Questions COVID Drug Claims of Biotechs
The commission has halted trading in the shares of three companies that have said they are developing a drug candidate for treating COVID-19.
By
Matthew Heller
| May 5, 2020
Read More
Risk & Compliance
Moderna Gets $483M to Fund Corona Vaccine
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
By
Matthew Heller
| April 17, 2020
Read More
Strategy
Four Pillars of Successful Corporate Decision-Making
Here's how to shift the decision-making process from a misunderstood art toward a mainstream science.
By
David Mellor
| March 11, 2020
Read More
Risk & Compliance
SEC Charges Former MiMedx Execs With Fraud
The C-suite executives allegedly improperly recognized revenue from distributors with which MiMedx had secret side arrangements.
By
Matthew Heller
| November 27, 2019
Read More
Strategy
Gilead to Invest $5B in Galapagos Partnership
The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
By
Matthew Heller
| July 15, 2019
Read More
Financial Reporting
Insys Shares Dive on ‘Going Concern’ Doubts
The opioid seller's auditor expressed "substantial doubt" about its ability to continue as a going concern.
By
Matthew Heller
| March 14, 2019
Read More
Next